skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Sequential hemibody and local irradiation with combination chemotherapy for small cell lung carcinoma: a preliminary analysis

Journal Article · · Int. J. Radiat. Oncol., Biol. Phys.; (United States)

Sequential hemibody irradiation (SHB) was integrated with combination chemotherapy and local irradiation (LRT) in the induction and consolidation phases of a therapeutic protocol for small cell lung carcinoma (SCLC). Forty-one previously untreated patients were entered into this program. Among 38 evaluable patients (20 with limited disease (LD) and 18 with extensive disease (ED)), the overall response rate was 63% (90% in LD and 33% in ED patients). The estimated overall survival is 8.1 months. The major toxicity has been myelosuppression - especially thrombocytopenia. The frequency of previously described acute radiation syndromes and radiation pneumonitis associated with hemibody irradiation have been substantially decreased at the current dosage with premedication and shielding techniques.

Research Organization:
Wake Forest Univ., Winston-Salem, NC
OSTI ID:
5548340
Journal Information:
Int. J. Radiat. Oncol., Biol. Phys.; (United States), Vol. 11:3
Country of Publication:
United States
Language:
English

Similar Records

Phase 2 Study of Accelerated Hypofractionated Thoracic Radiation Therapy and Concurrent Chemotherapy in Patients With Limited-Stage Small-Cell Lung Cancer
Journal Article · Sun Mar 01 00:00:00 EST 2015 · International Journal of Radiation Oncology, Biology and Physics · OSTI ID:5548340

Hemibody radiation, an active therapeutic modality for the management of patients with small cell lung cancer
Journal Article · Sat Oct 01 00:00:00 EDT 1983 · Int. J. Radiat. Oncol., Biol. Phys.; (United States) · OSTI ID:5548340

Randomized combined modality trial in small cell carcinoma of the lung. [Complications of chemotherapy and radiotherapy]
Journal Article · Tue Jan 01 00:00:00 EST 1980 · Cancer; (United States) · OSTI ID:5548340